Literature DB >> 27660931

PANLAR Consensus Recommendations for the Management in Osteoarthritis of Hand, Hip, and Knee.

Oscar Rillo1, Humberto Riera, Carlota Acosta, Verónica Liendo, Joyce Bolaños, Ligia Monterola, Edgar Nieto, Rodolfo Arape, Luisa M Franco, Mariflor Vera, Silvia Papasidero, Rolando Espinosa, Jorge A Esquivel, Renee Souto, Cesar Rossi, José F Molina, José Salas, Francisco Ballesteros, Francisco Radrigan, Marlene Guibert, Gil Reyes, Araceli Chico, Walter Camacho, Lorena Urioste, Abraham Garcia, Isa Iraheta, Carmen E Gutierrez, Raúl Aragón, Margarita Duarte, Margarita Gonzalez, Oswaldo Castañeda, Juan Angulo, Ibsen Coimbra, Roberto Munoz-Louis, Ricardo Saenz, Carlos Vallejo, Julio Briceño, Ramón P Acuña, Anibal De León, Anthony M Reginato, Ingrid Möller, Carlo V Caballero, Maritza Quintero.   

Abstract

OBJECTIVE: The objective of this consensus is to update the recommendations for the treatment of hand, hip, and knee osteoarthritis (OA) by agreeing on key propositions relating to the management of hand, hip, and knee OA, by identifying and critically appraising research evidence for the effectiveness of the treatments and by generating recommendations based on a combination of the available evidence and expert opinion of 18 countries of America.
METHODS: Recommendations were developed by a group of 48 specialists of rheumatologists, members of other medical disciplines (orthopedics and physiatrists), and three patients, one for each location of OA. A systematic review of existing articles, meta-analyses, and guidelines for the management of hand, hip, and knee OA published between 2008 and January 2014 was undertaken. The scores for Level of Evidence and Grade of Recommendation were proposed and fully consented within the committee based on The American Heart Association Evidence-Based Scoring System. The level of agreement was established through a variation of Delphi technique.
RESULTS: Both "strong" and "conditional" recommendations are given for management of hand, hip, and knee OA and nonpharmacological, pharmacological, and surgical modalities of treatment are presented according to the different levels of agreement.
CONCLUSIONS: These recommendations are based on the consensus of clinical experts from a wide range of disciplines taking available evidence into account while balancing the benefits and risks of nonpharmacological, pharmacological, and surgical treatment modalities, and incorporating their preferences and values. Different backgrounds in terms of patient education or drug availability in different countries were not evaluated but will be important.

Entities:  

Mesh:

Year:  2016        PMID: 27660931     DOI: 10.1097/RHU.0000000000000449

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  16 in total

1.  Consensus on non-pharmacological interventions for mild and moderate knee osteoarthritis among stakeholders/experts of various disciplines is still elusive -A preliminary report.

Authors:  Meenakshi Sharma; Amarjeet Singh; Sukhpal Kaur; Mandeep Singh Dhillon
Journal:  J Clin Orthop Trauma       Date:  2018-12-14

2.  EUROVISCO Recommendations for Optimizing the Clinical Results of Viscosupplementation in Osteoarthritis.

Authors:  Thierry Conrozier; Jordi Monfort; Xavier Chevalier; Raghu Raman; Pascal Richette; Demirhan Diraçoglù; Hervé Bard; Dominique Baron; Jörg Jerosch; Alberto Migliore; Yves Henrotin
Journal:  Cartilage       Date:  2018-06-21       Impact factor: 4.634

3.  Penetration of topical diclofenac into synovial tissue and fluid of osteoarthritic knees: a multicenter, randomized, placebo-controlled, pharmacokinetic study.

Authors:  Lothar Seefried; Mark Blyth; Rohit Maheshwari; Stephen M McDonnell; Guillaume Frappin; Martina Hagen; Nadine Maybaum; Sebastian Moreira; Hemant Pandit
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-08-29       Impact factor: 5.346

4.  Assessment of Common Comorbidity Phenotypes Among Older Adults With Knee Osteoarthritis to Inform Integrated Care Models.

Authors:  Trevor A Lentz; Anne S Hellkamp; Nrupen A Bhavsar; Adam P Goode; Ajay Manhapra; Steven Z George
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2021-01-19

5.  Efficacy and safety of a single intra-articular injection of 6 ml Hylan G-F 20 compared to placebo in Chinese patients with symptomatic knee osteoarthritis : C-SOUND study, a 26-week multicenter double-blind randomized placebo-controlled trial in China.

Authors:  Yan Ke; Wenxue Jiang; Yongsheng Xu; Yajun Chen; Qingsong Zhang; Qingyun Xue; Jianhao Lin; Wilson Ngai; Gaowei Nian; Mir Sohail Fazeli; Yao Xie; Zhenan Zhu
Journal:  BMC Musculoskelet Disord       Date:  2021-05-08       Impact factor: 2.362

Review 6.  [Conservative treatment options for arthritis of the ankle : What is possible, what is effective?]

Authors:  Jörg Jerosch
Journal:  Unfallchirurg       Date:  2022-01-18       Impact factor: 1.000

7.  Knee Osteoarthritis: An Investigation into the Clinical Practice of Physiotherapists in Canada.

Authors:  Brenda J Tittlemier; Kristy D Wittmeier; David B Robinson; Sandra C Webber
Journal:  Physiother Can       Date:  2021       Impact factor: 1.037

8.  Impact of obesity, structural severity and their combination on the efficacy of viscosupplementation in patients with knee osteoarthritis.

Authors:  Thierry Conrozier; Florent Eymard; Mickael Chouk; Xavier Chevalier
Journal:  BMC Musculoskelet Disord       Date:  2019-08-17       Impact factor: 2.362

9.  Salidroside Alleviates Cartilage Degeneration Through NF-κB Pathway in Osteoarthritis Rats.

Authors:  Hui Gao; Lu Peng; Chao Li; Qinlong Ji; Ping Li
Journal:  Drug Des Devel Ther       Date:  2020-04-14       Impact factor: 4.162

10.  Clinical effectiveness and safety of intra-articular injection of HYALGO in the management of knee osteoarthritis symptoms: A multicenter prospective study.

Authors:  Karel Pavelka; Rudolf Horváth; Jana Hurnáková; Laura Saracino; Nicola Giordan; Leona Procházková; Erik Moster; Eva Dokoupilová
Journal:  J Clin Orthop Trauma       Date:  2021-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.